2017
The prevalence and biomarkers’ characteristic of rapidly progressive Alzheimer’s disease from the Alzheimer’s Disease Neuroimaging Initiative database
Auteurs:
Ba, M., Li, X., Ng, K. P., Pascoal, T. A., Mathotaarachchi, S., Rosa-Neto, P., Gauthier, S., & Alzheimer's Disease Neuroimaging Initiative
Revue:
Alzheimer's & Dementia
ABSTRACT
INTRODUCTION: The prevalence and detailed biomarkers’ characteristic of rapidly progressive Alzheimer’s disease (rpAD) remain incompletely understood.
METHODS: A total of 312 mild AD patients from the Alzheimer’s Disease Neuroimaging Initiative database were chosen and dichotomized into rpAD and non-rpAD groups. We performed the prevalence and comprehensive biomarker evaluation.
RESULTS: The prevalence of rpAD was 17.6% in mild AD. Compared with non-rpAD, there were no differences in APOEε4/ε4, APOE ε3/ε4, and APOE ε2/ε4 genotype distribution, cerebrospinal fluid tau, phosphorylated tau (p-tau), amyloid-β, hippocampus volume, and amyloid deposition in rpAD. Yet, a lower p-tau/tau ratio was observed in rpAD (P = .04). rpAD showed region-specific hypometabolism ([18F]fluorodeoxyglucose-positron emission tomography [FDG-PET]) (P = .001). Receiver-operating characteristic analysis of FDG-PET demonstrated that left angular and left temporal cortices were the regions with higher area under the curve and predictive value for identifying clinical at-risk rpAD.
DISCUSSION: We identified that rpAD commonly existed in mild AD. Cerebral hypometabolism could provide potential clinical differential value for rpAD in the short-term follow-up period.
Partager
Recevez les
dernières nouvelles
Suivez les derniers développements de la recherche au sein du CCNA-CCNV. Notre section «Nouvelles» fournit des informations sur les études, les avancées et les principaux résultats de la recherche en matière de santé cérébrale.
